The Medical Device Innovation Consortium (MDIC) has partnered with PerkinElmer's Horizon Discovery to develop and manufacture somatic reference samples (SRSs) to simplify and support validation of next generation sequencing (NGS)-based cancer diagnostics. The SRSs are expected to be commercially available by early 2024, following a rigorous characterization and validation process in collaboration with the National Institute for Standards and Technology (NIST)...

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has launched the Cellaca^® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity. The cutting-edge Cellaca PLX system, designed by the company’s Nexcelom unit, combines best-in-class image cytometer hardware...

PerkinElmer’s Oxford Immunotec has announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories.The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs...

PerkinElmer, Inc. has announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital, a leading growth-oriented private equity firm, for total consideration of $2.45 billion in cash, $2.30 billion of which will be received at the closing and $150 million of which will be payable contingent on the exit valuation New Mountain Capital receives on a sale or other capital events related to the business...

PerkinElmer Inc., a global leader committed to innovating for a healthier world, has announced three new research use only (RUO) library preparation kits: NEXTFLEX^® Small RNA-Seq Kit v4, NEXTFLEX^® Rapid XP V2 DNA-Seq Kit and PG-Seq™ Rapid Kit v2. PerkinElmer offers a complete solutions for a range of library preparation applications including nucleic acid isolation, NGS automation, single cell RNA-seq, library preparation reagents, and nucleic acid QC...

PerkinElmer has announced the launch of the research use only (RUO) BioQule™ NGS System – an automated benchtop solution for next-generation sequencing (NGS) library preparation of up to eight samples. By incorporating automated thermocycling, integrated quality control through optical quantification and robust liquid handling technology into a single device...

Market leading innovator in laboratory digital transformation, Scitara, has announced a collaboration with scientific analytical technology leader, PerkinElmer. The move will support the integration of the PerkinElmer® Signals Research Suite™ informatics platform, which provides seamless, end-to-end scientific data and workflow management, with laboratory instruments, applications and resources via the Scitara Scientific Integration Platform™ SIP™...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, has announced the expansion of its in vivo imaging portfolio with the launch of the Vega® imaging system, a first-of-its kind ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced V21 of its ChemDraw® software featuring the ability to import, animate and share 3D chemical structures natively in the Microsoft® PowerPoint® application with one click. The key enhancement, to a tool used by millions of scientists around the world, helps chemists create more intelligent research reports quickly and easily...

Carterra, Inc. the world leader in label-free high throughput antibody screening and characterization, has announced that it has signed an exclusive Asia-Pacific and Oceania region distribution agreement with PerkinElmer, Inc. a global leader committed to innovating for a healthier world. With the agreement, PerkinElmer will market, sell, and service Carterra’s flagship LSA high-throughput surface plasmon resonance (SPR) platform and software used for accelerating the discovery of therapeutic antibodies...

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, has announced the research use only (RUO) launch of the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants. This complete next generation sequencing (NGS) solution will allow laboratories to increase sequencing throughput and make reliable variant identifications....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced that the performance of its SARS-CoV-2 RT-PCR assays are not impacted by the emergence of Omicron (B.1.1.529), a variant of concern that was recently identified by the World Health Organization (WHO). There are more than 30 Omicron mutations reported in the S gene of SARS-CoV-2. PerkinElmer’s assays do not target the S gene for SARS-CoV-2 detection and are not affected by these S gene mutations...

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced the launch of its PKeye™ Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows in real-time. The PKeye Workflow Monitor offers scientists and researchers 24/7 access and visibility into their laboratory operations....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced the launch of its Signals Research™ Suite , a full cloud based solution, deployed on Amazon Web Services. The suite is a secure, informatics platform, providing integrated, end-to-end scientific data and workflow management for pharmaceutical and industrial customers. Designed to help drive more informed and accelerated decision making around drug, compound and formulation candidates...

PerkinElmer, Inc. has announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay. Qualified laboratories can immediately begin using this single test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs and mid-turbinate swabs...

PerkinElmer, Inc. and Honeycomb Biotechnologies, Inc., announce the commercial launch of the first of its kind HIVE™ scRNAseq Solution for single-cell isolation and analysis. The HIVE solution leverages a portable, handheld device for the capture, storage and RNA-Seq library preparation of a diverse range of cell types, including fragile and labile cells such as granulocytes, nephrons, hepatocytes and neurons....

PerkinElmer, Inc., a global leading solutions provider in the life sciences, diagnostics, food and environmental testing markets, has announced the launch of Signals Image Artist™ software – a next-generation image analysis and management platform for drug discovery research. The new offering is designed to help scientists accurately process and analyse their high-content screening (HCS) and cellular imaging data in a matter of hours, instead of days or weeks, so they can make more informed decisions faster...

UPM Biomedicals is pleased to announce that it has entered into an agreement with PerkinElmer Health Sciences, Inc., for the life sciences leader to act as a distributor of the GrowDex® and GrowDase™ range of products. This new collaboration will offer researchers a complete solution for high throughput screening (HTS) of 3D cell cultures in early drug discovery, bringing together PerkinElmer’s cell imaging and automation solutions and knowledge, and UPM’s animal-free 3D reagent offerings and expertise...
 

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced that the U.S. Food and Drug Administration (FDA) has authorized the PerkinElmer® New Coronavirus Nucleic Acid Detection Kit for an additional indication that permits use of saliva as specimen type. The kit now has Emergency Use Authorization (EUA) for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva specimens collected...

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced four new ready-to-use AlphaLISA^® KRAS kits, designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly, and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers...

PerkinElmer announce it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments. BioLegend provides its academic and biopharmaceutical customers with best-in-class antibodies and reagents in high-growth areas such as cytometry...

Through this acquisition, PerkinElmer will be able to grow its overall Diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’s best-in-class chemiluminescence products in endocrinology, autoimmunity and infectious diseases to better serve customers around the world....

Horizon Discovery, a PerkinElmer, Inc. company, announce that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional level, ultimately leading to new therapeutic approaches....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science, a software company serving the global life sciences community....

EUROIMMUN, a PerkinElmer, Inc. company, announce the launch of the EUROPattern^TM Microscope Live (EPML) compact immunofluorescence microscope, available with the fourth generation of the Company’s well-established EUROLabOffice^TM 4.0 (ELO 4.0) laboratory management software. The combined system of hardware and software allows for ultrafast automated immunofluorescence image acquisition, pattern recognition and titer estimation as well as modern diagnostics at the screen.

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021.

PerkinElmer, Inc. has announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit. Using nucleic acid extracted from samples that previously tested positive, laboratories can use these assays to identify genomic mutations reported in relation to SARS-CoV-2 variants....

PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening. PerkinElmer, Inc. has announced the launch of the PerkinElmer^® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or nasopharyngeal (NP) swab specimens. The lateral flow immunoassay test can be used to screen or to aid in diagnoses of COVID-19 in asymptomatic or symptomatic individuals....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has launched the first cell painting kit as part of its new portfolio of PhenoVue™ cellular imaging reagents. This new range of reagents leverages PerkinElmer’s expertise in cellular imaging and high-content screening and works alongside the Company’s microplates, automation, software and industry-leading high-content screening instruments....

"Transforming R&D: Digital innovation in the pharmaceuticals and chemicals industries," a new report by MIT Technology Review Insights, explores how leading pharmaceuticals and chemicals companies are using artificial intelligence, quantum computing, and other digital technologies to transform scientific research and enhance R&D performance. The report, produced in association with PerkinElmer Informatics, is based on in-depth interviews with R&D executives at organizations including Novartis, Roche, Merck, BASF, and Syngenta....

PerkinElmer, Inc. has announced that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to test individuals without symptoms or other reasons to suspect COVID-19 infection. According to a new model from The Journal of the American Medical Association’s Open Network developed by researchers from the Centers for Disease Control and Prevention, close to 60% of total COVID-19 transmissions....

Through this Acquisition, PerkinElmer will grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection to better serve customers around the world. Moreover, the deal will enable PerkinElmer to combine its channel expertise and leading workflow and testing capabilities with Oxford Immunotec’s leading proficiencies in T cell immunology with its proprietary test kits for latent tuberculosis....

PerkinElmer, Inc., announce that the Lighthouse Lab in Charnwood, Loughborough, England is now processing COVID-19 testing samples as part of the Company’s collaboration with the Department of Health and Social Care (DHSC) in support of the UK Government’s NHS Test and Trace program. The facility, operated by PerkinElmer Genomics, began processing samples and with its team of 400 scientists, researchers, technicians and operations personnel, has the capacity to test up to 50,000 samples daily by early 2021....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has launched its newest ChemDraw^® application, ChemOffice^®+ Cloud, to simplify, facilitate and accelerate chemistry communication workflows. The ChemDraw platform is the leading chemistry drawing tool trusted around the world by scientists in commercial, government and academic lab settings across a number of research areas including life sciences, enviromental and materials....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 about ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen. The assay is available for countries accepting the CE mark, and the Company plans to file a request for this product with the U.S. Food and Drug...

PerkinElmer, Inc. has announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer^® New Coronavirus Nucleic Acid Detection Kit to increase the number of individuals who can be tested without increasing resources. This validation of batch testing using the industry’s most sensitive assay to date according to the FDA Reference Panel leverages its proven ability to detect low amounts of viral genetic material....

PerkinElmer, Inc. has announced  that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD). This test is currently under review by the U.S. FDA for Emergency Use Authorization (EUA). The multi-analyte panel enables labs to detect and differentiate between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus (RSV) in a single test...

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced that the first Turnkey Lighthouse lab in Newport, South Wales, is now processing COVID-19 testing samples as part of the Company’s collaboration with the Department of Health and Social Care (DHSC) in support of the UK Government’s Test and Trace strategy...

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced that its Hand Sanitizer Analyzer instrument can be used to test for the presence of methanol in alcohol-based hand sanitizer products with pass/fail results delivered in 30 seconds or less. Recent warnings and recalls from the FDA indicate that methanol can be toxic to consumers if absorbed through the skin and life threatening if ingested...

PerkinElmer, Inc. a global leader committed to innovating for a healthier world, has announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day. The finger-prick sample collection device allows for both decentralized sample collection and high-throughput testing. The product is being marketed as a CE-IVD test, and the Company plans to apply for....

An advanced laboratory dedicated to leading Wales’ national Covid-19 testing has been established in Cardiff, thanks to collaboration between Public Health Wales and one of the world’s leading diagnostics companies. Creating a national Covid-19 testing lab at the University Hospital of Wales is an important part of the Welsh Government’s Test, Trace, Protect strategy and has been made possible thanks to the support...

PerkinElmer, Inc. is actively working with our global customers – which include specialty and reference diagnostic labs, clinics, hospitals, pharmaceutical and biopharmaceutical labs, academia, and governmental and research institutes – to combat the pandemic. Our innovative detection, workflow, and research solutions are being used to drive better outcomes as the world responds to COVID-19....

U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G....

Beaumont Health’s Research Institute is launching America’s largest serological testing study to help answer many questions surrounding the spread of COVID-19 and potentially help treat patients battling the virus. New study aims to determine the total population with COVID-19 antibodies across a health system, identify potential convalescent plasma donors, better understand disease transmission and contribute to a scientifically-based methodology for returning people to work....

Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this kit to detect SARS-CoV-2, the virus that causes COVID-19. PerkinElmer’s RT-PCR test is marketed as an in vitro diagnostic (IVD) device by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD) and is available in over 30 countries worldwide....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has introduced new workstations and a high content screening system at SLAS2020 in San Diego. These technologies automate workflows so that disease research and drug discovery professionals can improve productivity, increase reproducibility, and garner key insights. PerkinElmer highlighted these new systems, along with several key offerings from its comprehensive portfolio of instruments and reagents....

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that a collaboration for a prospective study in Brazil aiming to validate the Fetal Medicine Foundation’s (FMF’s) algorithm for pre-term preeclampsia.  The FMF algorithm, which is based on a European population, will now be applied to a study group representative of the Brazilian population....

Industry-Leading Adapters Mitigate Index Hopping and Spread of Signal in Next Gen Sequencing Applications. PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced its NEXTflex® unique dual index barcodes, the latest addition to the NEXTflex family of library prep solutions....

First Personal Genomics Product Will Focus on 59 Genes Identified by the American College of Medical Genetics and Genomics (ACMG) as Highly Penetrant. PerkinElmer, Inc. has announced  a collaboration with Helix, a personal genomics company, to develop and commercialize exome sequencing-based tests...

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced that Parent Project Muscular Dystrophy (PPMD) has selected the Company to provide genetic testing for its Decode Duchenne program...

Study Results in Leading Scientific Publication Underscores Value of PerkinElmer’s Vanadis NIPT Solution. PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced the publication of a research study describing the technology behind the Vanadis NIPT system. The article titled “Imaging Single DNA Molecules for High Precision NIPT” was published online in Nature Scientific Reports...

In-Depth Genomics Leverages PerkinElmer’s Comprehensive Sequencing Services to Provide Whole Genome Sequencing to Neurology Patients 

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, have announced an innovative collaboration with In-Depth Genomics (IDG) to support IDG’s Whole Genome Sequencing (WGS) Diagnostic Program that will bring genetic diagnosis.....

High Throughput Mass Spectrometry-Based Clinical Solution Can Run Hundreds of Samples Per Day 

PerkinElmer, Inc.has announced the launch of its QSight^® 210 MD system, designed to provide routine high throughput quantitation to laboratories. The QSight 210 MD system includes tandem mass spectrometry (MSMS) technology designed to enable laboratories to run hundreds of samples per day....

From field to lab to the loading dock, the perfect system for NIR materials testing.

Whether you’re performing ID testing or quantitative analysis for food, pharmaceuticals, polymers, or petroleum, you often need to test where the samples are – onsite, and on the fly. But you can’t sacrifice high performance for portability – which means your FT-NIR needs to deliver the same levels of sensitivity, resolution, and throughput, inside and outside the lab....

Innovative Molecular Spectroscopy Solution Provides Advanced Analysis for Food, Pharma and Industrial Applications

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of the Spectrum Two N™ FT-NIR system. This instrument is designed for laboratory technicians and staff conducting molecular spectroscopy analysis on a wide range of pharmaceutical, food and industrial samples....

PerkinElmer Genetics Provides Complete Genomic Lab Testing Solution

PerkinElmer, Inc. announce the launch of PerkinElmer Genetics' clinical genomics services. Through its integrated laboratories in the U.S., India and China, PerkinElmer offers a global genomic lab testing platform that performs screening and diagnostic testing, specializing in newborn screening....

Expand the range of what your lab can accomplish. Extend your resources so that you can do even more.

All with the Avio 500 ICP-OES – a truly simultaneous, dual view, and compact ICP-OES. It utilizes a vertical plasma and is engineered to handle even the most difficult, high-matrix samples without dilution, delivering productivity, performance, and faster return on investment....

Project “ASPRE” Study Utilized PerkinElmer’s DELFIA Xpress PlGF 1-2-3 Assay to Identify Women who Would Benefit from Low-Dose Aspirin

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the publication of the Fetal Medicine Foundation’s (FMF’s) Project “ASPRE” study results in The New England Journal of Medicine. These compelling findings revealed that administering low-dose aspirin (150 mg) led to a 62% reduction in the rate of pre-term preeclampsia....

First Commercial IVD Kit to Use Mass Spectrometry to Screen for Six LSDs in Newborn Babies from a Single Dried Blood Spot Sample

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its new NeoLSD™ MSMS kit.  This solution is the first CE marked commercial in vitro diagnostic (IVD) kit to utilize mass spectrometry instrumentation for the six most commonly screened lysosomal storage disorders (LSDs)....

PerkinElmer, Inc. have announced that it has entered into a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN.

The total purchase price of the transaction based on all outstanding shares being acquired will be approximately $1.3 billion in cash.Based in Lübeck, Germany, with approximately 2,400 employees, EUROIMMUN is widely recognized as a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing.....

PerkinElmer, Inc. Provides Research-Use-Only Automated Immunoassay to Detect Creatine Kinase Muscle Isozyme in Dried Blood Spots

A new study published in Clinical Chemistry has revealed a potential automated assay for identifying Duchenne muscular dystrophy (Duchenne) in newborn babies. Duchenne is a progressive, X-chromosome linked neuromuscular disorder with a worldwide average incidence rate of approximately 1 in 5,000 babies....

PerkinElmer Highlights Innovative Mass Spectrometry and Liquid & Gas Chromatography Technologies for Food, Environmental and Industrial Customers at analytica China

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced the launch of its new QSight™ Triple Quadrupole LC/MS/MS instrument at a press conference during analytica China, the international trade fair for laboratory technology, analysis, biotechnology and diagnostics held at the Shanghai New International Expo Centre....

Advanced Detection, Imaging and Diagnostics Solutions for Today’s Modern Laboratory

WHAT: PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it will showcase several of its innovative solutions at Analytica 2016, the international trade fair for laboratory technology, analysis and biotechnology in Munich, Germany. “We are pleased to highlight our wide range of instruments, software and services with this...

Magritek announces company expansion with the appointment of new hires to the sales and marketing team. 

SCID screening improves medical outcomes with early detection, intervention

PerkinElmer, Inc., a global leader in improving the health and safety of people and the environment, today introduced the first commercially available screening test for Severe Combined Immunodeficiency (SCID). The EnLite™ Neonatal TREC System expands the newborn screening portfolio of commercially available tests and will be introduced under CE marking, for sale in select countries in Europe and the Middle East. SCID impacts an estimated 1 in 50,000 to 1 in 100,000 newborns globally every year...

The New AxION iQT GC/MS/MS System Combines the Quantitative Power of a Triple Quad with the Identification Capabilities of a Q-TOF in a Faster, Modular and Easier to Operate Instrument

At the 2013 American Society for Mass Spectrometry Conference, PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, introduced the AxION iQT gas chromatography tandem mass spectrometer (GC/MS/MS). The AxION iQT system provides greater quantitative capabilities to that of a triple quadrupole, while quickly identifying compounds like a quadrupole time-of-flight (Q-TOF) at a rate of up to 500 compounds per second. The new mass spectrometer provides laboratories with easier to use technology, faster results, and more specific, selective data needed to make more accurate decisions faster.....

New consulting services will leverage expertise derived from the largest laboratory services and informatics offering install base

New, unique offerings enable scientists to analyze environmental and industrial samples with greater specificity